Table 3

Symptomatic and structural efficacy of MTX optimisation

OutcomesOptimal MTX dose
n=76
n (%) at M12
n (%) at M24
Non-optimal MTX dose
n=212
n (%) at M12
n (%) at M24
aOR* M0–M12
(95% CI)
aOR* M12–M24
(95% CI)
ACR-EULAR Boolean remission20 (27.4)
23 (32.4)
16 (8.0)
34 (18.1)
4.28 (1.86 to 9.86)2.75 (1.33 to 5.70)
SDAI remission23 (31.9)
27 (38.0)
27 (10.8)
33 (17.6)
5.14 (2.27 to 11.60)3.08 (1.54 to 6.14)
DAS28 remission42 (58.3)
40 (57.1)
57 (28.8)
74 (39.4)
4.09 (2.01 to 8.29)2.71 (1.35 to 5.45)
Normal functioning†56 (73.7)
52 (68.4)
107 (50.5)
110 (51.9)
4.36 (2.03 to 9.39)2.02 (1.03 to 3.96)
Absence of rapid radiographic progression (∆SHS score <5)46 (68.7)
46 (75.4)
132 (70.6)
145 (80.6)
1.17 (0.60 to 2.28)1.70 (0.79 to 3.65)
  • *aOR, adjusted on age, centre, swollen joint count, C-reactive protein level, positivity for anticitrullinated protein antibody or rheumatoid factor, erosion, smoking, Health Assessment Questionnaire (HAQ) score, 1987 American College of Rheumatology criteria.

  • †HAQ≤0.5.

  • ACR, American College of Rheumatology; aOR, adjusted OR; DAS28, Disease Activity Score in 28 joints; EULAR, European League Against Rheumatism;  M12, 12 months; M24, 24 months; M0, baseline; MTX, methotrexate; SDAI, Simplified Disease Activity Index; SHS, Sharp/van der Heijde score.